WHO’s decision to approve three Multiple Sclerosis (MS) Disease-Modifying Therapies – A.10 Cladribine, glatiramer, and rituximab – as part of its Essential Medicines List, is a “significant milestone for the global MS community”.
The National Multiple Sclerosis Society (NMSS) has been launched in Abu Dhabi, to deliver support programmes, improve healthcare services and provide a community for people affected by MS across the UAE.